tbuckley/cabot-search huggingface dataset:
Adolescent Health—Not Just for Adolescent Specialists—Reply
Authors: Megan Moreno, Lindsay A. Thompson
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
1897P Germline and somatic mutational landscape in a cohort of malignant pleural mesothelioma patients
Authors: M. Gausachs, D. Azuara, A. López-Doriga, D. Cordero, G. Vargas, S. González, M. Pineda, L. Feliubadaló, S. Padrones, F. Rivas, A. Urena, R. Llatjós, R. Palmero, M. Arellano, A. Teule, J. Brunet, G. Capellá, X. Solé, C. Lázaro, E. Nadal
Journal: Annals of Oncology (2020)
Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes
Authors: Robert S. Pulido, Roeben N. Munji, Tamara C. Chan, Clare R. Quirk, Geoffrey A. Weiner, Benjamin D. Weger, Meghan J. Rossi, Sara Elmsaouri, Mario Malfavon, Aaron Deng, Caterina P. Profaci, Marie Blanchette, Tongcheng Qian, Koji L. Foreman, Eric V. Shusta, Michael R. Gorman, Frédéric Gachon, Stefan Leutgeb, Richard Daneman
Journal: Neuron (2020)
55P Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies
Authors: J. Edeline, S. Hirano, A. Bertaut, M. Konishi, M. Benabdelghani, K. Uesaka, J. Watelet, M. Ohtsuka, P. Hammel, Y. Kaneoka, J-P. Joly, M. Yamamoto, C. Jouffroy, Y. Ambo, C. Louvet, M. Ando, D. Malka, M. Nagino, J.M. Phelip, T. Ebata
Journal: Annals of Oncology (2020)
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
Authors: R.L. Coleman, D. Lorusso, C. Gennigens, A. González-Martín, L. Randall, D. Cibula, B. Lund, L. Woelber, S. Pignata, F. Forget, A. Redondo, R. Rangwala, S.D. Vindeløv, M. Chen, J.R. Harris, L. Nicacio, M.S.L. Teng, M. Smith, B.J. Monk, I.B. Vergote
Journal: Annals of Oncology (2020)
LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
Authors: J. Bourhis, C. Sire, Y. Tao, L. Martin, M. Alfonsi, J.B. Prevost, M. Rives, C. Lafond, J.M. Tourani, J. Biau, L. Geoffrois, A. Coutte, X. Liem, E. Vauleon, F. Drouet, A. Pechery, J. Guigay, M. Wanneveich, A. Aupérin, X. Sun
Journal: Annals of Oncology (2020)
Healthy lifestyle and life expectancy in people with multimorbidity in the UK Biobank: A longitudinal cohort study
Authors: Yogini V. Chudasama, Kamlesh Khunti, Clare L. Gillies, Nafeesa N. Dhalwani, Melanie J. Davies, Thomas Yates, Francesco Zaccardi
Journal: PLoS Medicine (2020)

Whether a healthy lifestyle impacts longevity in the presence of multimorbidity is unclear. We investigated the associations between healthy lifestyle and life expectancy in people with and without multimorbidity.A total of 480,940 middle-aged adults (median age of 58 years [range 38-73], 46% male, 95% white) were analysed in the UK Biobank; this longitudinal study collected data between 2006 and 2010, and participants were followed up until 2016. We extracted 36 chronic conditions and defined multimorbidity as 2 or more conditions. Four lifestyle factors, based on national guidelines, were used: leisure-time physical activity, smoking, diet, and alcohol consumption. A combined weighted score was developed and grouped participants into 4 categories: very unhealthy, unhealthy, healthy, and very healthy. Survival models were applied to predict life expectancy, adjusting for ethnicity, working status, deprivation, body mass index, and sedentary time. A total of 93,746 (19.5%) participants had multimorbidity. During a mean follow-up of 7 (range 2-9) years, 11,006 deaths occurred. At 45 years, in men with multimorbidity an unhealthy score was associated with a gain of 1.5 (95% confidence interval [CI] -0.3 to 3.3; P = 0.102) additional life years compared to very unhealthy score, though the association was not significant, whilst a healthy score was significantly associated with a gain of 4.5 (3.3 to 5.7; P < 0.001) life years and a very healthy score with 6.3 (5.0 to 7.7; P < 0.001) years. Corresponding estimates in women were 3.5 (95% CI 0.7 to 6.3; P = 0.016), 6.4 (4.8 to 7.9; P < 0.001), and 7.6 (6.0 to 9.2; P < 0.001) years. Results were consistent in those without multimorbidity and in several sensitivity analyses. For individual lifestyle factors, no current smoking was associated with the largest survival benefit. The main limitations were that we could not explore the consistency of our results using a more restrictive definition of multimorbidity including only cardiometabolic conditions, and participants were not representative of the UK as a whole.In this analysis of data from the UK Biobank, we found that regardless of the presence of multimorbidity, engaging in a healthier lifestyle was associated with up to 6.3 years longer life for men and 7.6 years for women; however, not all lifestyle risk factors equally correlated with life expectancy, with smoking being significantly worse than others.
Case 30-2020: A 54-Year-Old Man with Sudden Cardiac Arrest
Authors: Elazer R. Edelman, Neel M. Butala, Laura L. Avery, Andrew L. Lundquist, Anand S. Dighe
Journal: New England Journal of Medicine (2020)

A 54-year-old man was evaluated at the hospital after cardiac arrest associated with ventricular fibrillation. The patient had been in a fast-food restaurant when he gasped suddenly and lost consciousness. Emergency medical services personnel arrived, and cardiopulmonary resuscitation was initiated. A diagnosis was made.
Decarceration and community re-entry in the COVID-19 era
Authors: Carlos Franco-Paredes, Nazgol Ghandnoosh, Hassan Latif, Martin Krsak, Andres F Henao-Martinez, Megan Robins, Lilian Vargas Barahona, Eric M Poeschla
Journal: The Lancet Infectious Diseases (2020)

Jails and prisons are exceptionally susceptible to viral outbreaks, such as severe acute respiratory syndrome coronavirus 2. The USA has extremely high rates of incarceration and COVID-19 is causing an urgent health crisis in correctional facilities and detention centres. Epidemics happening in prisons are compounding the elevated risks that COVID-19 poses to people of colour, older people, and those with comorbidities. Intersectoral community re-entry efforts in the USA and other countries have shown that releasing people from correctional facilities as a pandemic-era public health intervention is safe and can support both public safety and community rebuilding. Therefore, substantial decarceration in the USA should be initiated. A point of focus for such efforts is that many people in prison are serving excessively long sentences and pose acceptable safety risks for release. Properly managed, correctional depopulation will prevent considerable COVID-19 morbidity and mortality and reduce prevailing socioeconomic and health inequities.
Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis
Authors: Junhao Zheng, Jingwei Cai, Liye Tao, Mubarak Ali Kirih, Zefeng Shen, Junjie Xu, Xiao Liang
Journal: International Journal of Surgery (2020)
Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
Authors: Juliette Roels, Morgan Thénoz, Bronisława Szarzyńska, Mattias Landfors, Stien De Coninck, Lisa Demoen, Lien Provez, Anna Kuchmiy, Steven Strubbe, Lindy Reunes, Tim Pieters, Filip Matthijssens, Wouter Van Loocke, Büşra Erarslan-Uysal, Paulina Richter-Pechańska, Ken Declerck, Tim Lammens, Barbara De Moerloose, Dieter Deforce, Filip Van Nieuwerburgh, Laurence C. Cheung, Rishi S. Kotecha, Marc R. Mansour, Bart Ghesquière, Guy Van Camp, Wim Vanden Berghe, Jerzy R. Kowalczyk, Tomasz Szczepański, Utpal P. Davé, Andreas E. Kulozik, Steven Goossens, David J. Curtis, Tom Taghon, Małgorzata Dawidowska, Sofie Degerman, Pieter Van Vlierberghe
Journal: Blood Cancer Discovery (2020)

Cancer cells display DNA hypermethylation at specific CpG islands in comparison to their normal healthy counterparts, but the mechanism that drives this so-called CpG island methylator phenotype (CIMP) remains poorly understood. Here, we show that CpG island methylation in human T-cell acute lymphoblastic leukemia (T-ALL) mainly occurs at promoters of Polycomb Repressor Complex 2 (PRC2) target genes that are not expressed in normal or malignant T-cells and which display a reciprocal association with H3K27me3 binding. In addition, we revealed that this aberrant methylation profile reflects the epigenetic history of T-ALL and is established already in pre-leukemic, self-renewing thymocytes that precede T-ALL development. Finally, we unexpectedly uncover that this age-related CpG island hypermethylation signature in T-ALL is completely resistant to the FDA-approved hypomethylating agent Decitabine. Altogether, we here provide conceptual evidence for the involvement of a pre-leukemic phase characterized by self-renewing thymocytes in the pathogenesis of human T-ALL.
990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
Authors: P.R. Galle, R.D. Kim, M.W. Sung, W.P. Harris, D. Waldschmidt, R. Cabrera, U. Mueller, K. Nakajima, T. Ishida, A.B. El-Khoueiry
Journal: Annals of Oncology (2020)
520TiP A multicenter study to evaluate the impact of circulating tumor DNA guided therapy (BESPOKE) in patients with stage II and III colorectal cancer
Authors: P.M. Kasi, S. Sawyer, J. Guilford, M. Munro, S. Ellers, N. Hook, S. Krinshpun, S. Moshkevich, P.R. Billings, A. Aleshin
Journal: Annals of Oncology (2020)
“Just because I don't bleed, doesn't mean I don't go through it”: Expanding knowledge on trans and non-binary menstruators
Authors: A.J. Lowik
Journal: International Journal of Transgender Health (2020)

Critical menstruation studies is a field in its nascence, marginalized within the broader area of reproductive health research. Menstruation-related research is virtually absent from trans studies, itself a marginalized field of inquiry. This article focuses on the experiences of trans and non-binary menstruators, to contribute to this burgeoning area of study.This article involves secondary data analysis of a qualitative dissertation research study on trans people's reproductive lives, health, and decision-making processes. Of the fourteen participants in the broader study, eleven discussed their perceptions of and experiences with menstruation and menstrual health. Those experiences where subjected to thematic narrative analysis, with a focus on themes that were substantively significant.Participants describe experiences with amenorrhea associated with the use of testosterone, menstrual resumption following the cessation of testosterone and for other reasons, menstruation-related dysphoria management strategies beyond medical interventions, as well as barriers to menstruation-related health care. One participant describes bloodless periods as a trans woman, a phenomenon altogether absent from the clinical and experiential literature in this field. The article explores how cisnormativity, repronormativity and transnormativity informed the participants experiences of menstruation and reproductive health care.Contributing novel stories to the literature, this article illustrates how clinically focused research fails to attend to the experiential components of menstruation for trans and non-binary people. Expanded knowledge is beneficial to the development of gender-inclusive menstruation research, clinical interventions, healthcare environments, and activist efforts.
LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
Authors: J. Baena Espinar, V. Torri, J. Whisenant, F.R. Hirsch, J. Rogado, J. de Castro Carpeño, B. Halmos, G.L. Ceresoli, A. Gomez Rueda, M. Tiseo, E. Felip, M. Majem Tarruella, I. Monnet, U. Tapan, H. Wakelee, L-C. Huang, M.C. Garassino, S. Peters, L. Horn, M. Hellmann
Journal: Annals of Oncology (2020)
1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Authors: R. Blanco, E. Nadal, S. Loutfi, M. Domine Gomez, J. Saldaña, J. Alfaro Gamero, J.L. Gonzalez-Larriba, B. Campos Balea, R. Girones Sarrio, J. Hidalgo, A. Barba, M. Majem Tarruella, D. Marquez, M. Martin Ureste, A. Olaverri Hernández, J. Balsalobre, O.J. Juan Vidal
Journal: Annals of Oncology (2020)
1756P Cancer patients infected with COVID-19 at La Princesa Hospital: Real-world data study
Authors: P. Toquero Diez, B. Vera Cea, A. Garrido Garcia, E.R. Méndez Carrascosa, D. Bañón Torres, R. Colomer Bosch, N. Romero Laorden, B. Hernández
Journal: Annals of Oncology (2020)
675P HER2 expression in circulating tumour cells is associated with poor outcomes in patients with metastatic castration resistant prostate cancer
Authors: D. Maillet, N. Allioli, J. Peron, A. Plesa, M. Decaussin, S. Tartas, A. Ruffion, S. Crouzet, G. Freyer, V. Vlaeminck-Guillem
Journal: Annals of Oncology (2020)
1731P Molecular diagnostics for cancer patients and high-risk individuals during the SARS-CoV-2 pandemic at the Institute for Oncology and Radiology of Serbia
Authors: M. Cavic, A. Krivokuca, A. Damjanovic-Velickovic, M. Pavlovic, M. Mihajlovic, J. Rakobradovic, I. Boljevic, E. Malisic, M. Tanic, R. Jankovic
Journal: Annals of Oncology (2020)
400MO Curative chemoradiation for low rectal cancer: Early clinical outcomes from a multicentre phase II trial
Authors: L.H. Jensen, L.Ø. Poulsen, S.N. Risum, J.D. Nielsen, T. Mynster, J. Ploeen, H. Rahr, B.M. Havelund, A. Appelt, J. Lindebjerg, S.R. Rafaelsen, A. Jakobsen
Journal: Annals of Oncology (2020)
1394P Deep learning model to predict clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Authors: A. Elkrief, K. Phan, L. Di Jorio, R. Simpson, M. Chassé, J. Malo, C. Richard, M. Kosyakov, F. Chandelier, K. Kafi, B. Routy
Journal: Annals of Oncology (2020)
1764P Prevalence, severity and evolution of Coronavirus disease 19 (COVID-19) infection in cancer patients from Mediterranean population
Authors: J. Garde Noguera, M.L. Fernandez-Murga, B. Honrubia Peris, J. García Sánchez, N. Piera Molons, M.D.C. Gomez Soler, T. Fenollosa Sanz, P. Llor Rodriguez, V. Carañana Ballerini, E. Cabrera Espinos, A. Albert Balaguer, A. Fernandez Do Nascimento, A. Pellicer Boigues, A. Llombart Cussac
Journal: Annals of Oncology (2020)
919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Authors: R. Ferrarotto, L.J. Wirth, J. Muzaffar, C.P. Rodriguez, B. Xia, C.A. Perez, D.W. Bowles, E. Winquist, S.J. Hotte, R. Metcalf, C. Even, G.B. Gordon, G. Gordon, A. Ho
Journal: Annals of Oncology (2020)
421P Upfront chemotherapy vs. surgery for very low lying locally advanced rectal cancer without preoperative chemoradiation: The NAIR phase II/III trial
Authors: Y. Tsukada, Y. Nishizawa, Y. Akagi, K. Koda, M. Ohue, E. Shinto, S. Nishikawa, T. Hanai, T. Sasaki, Y. Nishizawa, K. Ikeda, H. Bando, T. Yamanaka, T. Yoshino, N. Saito, M. Ito
Journal: Annals of Oncology (2020)
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Authors: Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter E. Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver
Journal: Clinical Cancer Research (2020)

On December 18, 2019, the FDA granted accelerated approval to enfortumab vedotin-ejfv (PADCEV; Astellas and Seattle Genetics) for treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a programmed cell death protein 1 or programmed death ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Substantial evidence of effectiveness for this application is obtained from Cohort 1 of the single-arm, multicenter Study EV-201. Patients received enfortumab vedotin (EV) 1.25 mg/kg (up to a maximum dose of 125 mg) intravenously on days 1, 8, and 15 of 28-day cycles until disease progression or unacceptable toxicity. Confirmed objective response rate in the 125-patient efficacy population determined by blinded independent central review was 44% [95% confidence interval (CI), 35.1-53.2], with complete responses in 12%. Median response duration was 7.6 months (95% CI, 6.3-not estimable). Grade 3-4 adverse reactions occurred in 73% of patients. Hyperglycemia, peripheral neuropathy, ocular disorders, skin reactions, infusion site extravasations, and embryo-fetal toxicity are labeled as warnings and precautions for EV. The article summarizes the data and the FDA thought process supporting accelerated approval of EV. This approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
Authors: J.A. Ludwig, N. Federman, P. Anderson, M.E. Macy, L.E. Davis, R.F. Riedel, J.A. Muscal, N.C. Daw, R. Ratan, J. Toretsky, X. Ianopulos, F.J. Hsu, J.B. Breitmeyer, P. Meyers
Journal: Annals of Oncology (2020)
601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours
Authors: H. Gelderblom, J.A. Gietema, I.M.E. Desar, N.M. Ajmone, M. Jalving, J.R. Kroep, V. Nicolas, A. Vaslin, K. Tobal, D. Purcea, S.F. van Haren, L. Damstrup
Journal: Annals of Oncology (2020)
Sanjiv “Sam” Gambhir, MD, PhD: In Memoriam (1962–2020)
Authors: Anna M. Wu, Andrei Iagaru, Harvey Herschman, Ralph Weissleder, Charles L. Sawyers
Journal: Cancer Research (2020)

![][1] 

Photo courtesy of Sandip Biswal, MD. 

The oncology community lost a champion on July 18, 2020, when Sanjiv “Sam” Gambhir lost his personal battle with cancer. Dr. Gambhir was the Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research and Chair of
Promising biomarkers of human aging: In search of a multi-omics panel to understand the aging process from a multidimensional perspective
Authors: N.A. Rivero-Segura, O.Y. Bello-Chavolla, O.S. Barrera-Vázquez, L.M. Gutierrez-Robledo, J.C. Gomez-Verjan
Journal: Ageing Research Reviews (2020)
1726P Expanding the role of medical oncologist in the management of COVID-19
Authors: L. Ghiglione, E. Auclin, J. Aguilar-Company, N. Epaillard, D. Casadevall Aguilar, L. Masfarré, M. Rodriguez Castells, M. Tagliamento, S. Pilotto, R. Lopez Castro, X. Mielgo Rubio, C. Urbano Centella, J.C. Laguna, D. García-Illescas, M.V. Bluthgen, T. Gorría Puga, J.N. Minatta, C.A. Cruz, A. Prat, L. Mezquita
Journal: Annals of Oncology (2020)
1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Authors: N. Gaspar, Q. Campbell-Hewson, S.S. Bielack, M. Campbell, F. Bautista, C. Meazza, K. Janeway, F.S. Dela Cruz, S.B. Whittle, D.A. Morgenstern, L. Dutta, J. McKenzie, K. O'Hara, J. Huang, C.E. Okpara, B. Bidadi, K-N. Koh, B. Morland
Journal: Annals of Oncology (2020)
2000P Real-world EGFR testing in patients with advanced EGFRm NSCLC in Belgium (REVEAL)
Authors: K. Cuppens, L. Lodewyckx, I. Demedts, L. Decoster, B. Colinet, K. Deschepper, A. Janssens, P. Pauwels, D. Galdermans, T. Pieters
Journal: Annals of Oncology (2020)
311P Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer
Authors: H. Yamashiro, Y. Yamamoto, A. Schneeweiss, V. Müller, O. Gluz, P. Klare, B. Aktas, D. Magdolna, L. Büdi, B. Pikó, L. Mangel, M. Toi, S. Morita, S. Ohno
Journal: Annals of Oncology (2020)
1455P A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
Authors: J. Feng, B. Shen, J. Xu, Q. Wang, G. Ling, Y. Mao, M. Cai, Y. Yang, J. Mei, Z. Han, Y. Wu, L. Shi
Journal: Annals of Oncology (2020)
1023MO AMC 095: A report of nivolumab (nivo) in advanced HIV associated solid tumours (ST)
Authors: L. Rajdev, S. Lensing, J.C. Ramos, R. Baiocchi, C-C.J. Wang, L. Ratner, P.G. Rubinstein, R. Ambinder, D. Henry, H. Streicher, R.F. Little, E. Chiao, M.S. Lee, D.P. Dittmer, M.H. Einstein, J.A. Sparano, R.T. Mitsuyasu
Journal: Annals of Oncology (2020)
Corrigendum to “Multicellularity-interweaved bone regeneration of BMP-2-loaded scaffold with orchestrated kinetics of resorption and osteogenesis”[Biomaterials Volume 216 (2019) 119216]
Authors: Haoyi Niu, Yifan Ma, Guangyu Wu, Bing Duan, Ying Wang, Yuan Yuan, Changsheng Liu
Journal: Biomaterials (2020)
741P Clinical outcomes stratified by Charlson Comorbidity Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP)
Authors: K. Fife, B.E. Szabados, B. Klair, V. Perrot, A. Michael, B. Venugopal
Journal: Annals of Oncology (2020)
1630P Clinical efficacy comparison of avapritinib versus other tyrosine kinase inhibitors (TKIs) in gastrointestinal stromal tumours (GIST) with PDGFRA D842V mutation: A retrospective analysis of clinical trial and real-world data
Authors: M. von Mehren, M. Heinrich, H. Shi, S. Iannazzo, R. Mankoski, S. Dimitrijević, G. Hoehn, S. Chiroli, S. George
Journal: Annals of Oncology (2020)
LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
Authors: Y. Yang, J. Sun, Z. Wang, J. Fang, Q. Yu, B. Han, S. Cang, G. Chen, X. Mei, Z. Yang, R. Ma, M. Bi, X. Ren, J. Zhou, B. Li, H. Zhou, S. Wang, W. Xu, B. Peng, L. Zhang
Journal: Annals of Oncology (2020)